Company Performance Metrics
- Paul Foulger: Chief Financial OfficerPast Role: EKF Diagnostics, CFO
Matthew Walls: Chief Executive Officer and Co-Founder
GEN inCode specializes in cardiovascular disease risk. Cardiovascular disease is the leading cause of death and disability worldwide.
GEN inCode products combine genetic and clinical data to risk assess patients and provide healthcare practitioners with advanced clinical information to evaluate and predict the onset of cardiovascular disease.
Our
products help inform patients of their health risk enabling them to make behavioral or ‘lifestyle’ changes whilst providing doctors with greater genetic insight and clinical information to determine the most effective treatment pathway (precision medicine).
GEN inCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. Our polygenic tests combine clinical-genetic algorithms with AI to provide an advanced patient risk assessment to predict disease onset.
